News & Views

Heart Failure May Increase Risk for Certain Cancers

Patients with heart failure have a 75% increased risk of developing cancer, researchers reported in ESC Heart Failure. And cancer incidence rates were even higher for specific disease sites.

August 04, 2021

Trending Topics

View All Topics

Nursing Informaticists Are the Backbone of Technology-Driven Care

Oncology nursing roles

Nursing Informaticists Are the Backbone of Technology-Driven Care

August 03, 2021

Beyond the Bedside: Oncology Nurses Have Endless Opportunities in Unexpected Careers

Clinical practice

Beyond the Bedside: Oncology Nurses Have Endless Opportunities in Unexpected Careers

August 03, 2021

We Don’t Have a Crystal Ball, but ONS Is Prepared for Nursing’s Future

We Don’t Have a Crystal Ball, but ONS Is Prepared for Nursing’s Future

August 02, 2021

Oncology Nursing Society Response to Mandated COVID-19 Vaccinations for Nurses and All Healthcare Professionals

ONS Response to Mandated COVID-19 Vaccinations for Nurses and All Healthcare Professionals

FDA Alerts About Possible Increased Risk of Death Associated With Melphalan Flufenamide

U.S. Food and Drug Administration (FDA)

FDA Alerts About Possible Increased Risk of Death Associated With Melphalan Flufenamide

The Seven Dimensions of Rest

Nurse well-being

The Seven Dimensions of Rest

New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers

New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers

FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer

Oncology Drug Reference Sheet: Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Subcutaneous Injection

Drug Reference Sheet

Oncology Drug Reference Sheet: Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Subcutaneous Injection

What Is CRISPR?

What Is CRISPR?

FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma

U.S. Food and Drug Administration (FDA)

FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma

FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

U.S. Food and Drug Administration (FDA)

FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

U.S. Food and Drug Administration (FDA)

FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

ONS Virtual Conference Offers Live and On-Demand Content for Oncology Nurses

ONS Virtual Conference Offers Live and On-Demand Content for Oncology Nurses

Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

Cancer research

Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

The Case of the Mysterious Myalgia

The Case of the Mysterious Myalgia

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

U.S. Food and Drug Administration (FDA)

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

Meet Your ONS Leader: Valerie Burger

Meet Your ONS Leader: Valerie Burger

Diagnose and Treat Hypercalcemia of Malignancy

Advanced practice nursing (APN)

Diagnose and Treat Hypercalcemia of Malignancy

New Evidence-Based Practice Learning Library Now Available

New Evidence-Based Practice Learning Library Now Available

Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

Nurse Research AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

Oncology nurse researcher

Nurse Researcher AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

U.S. Food and Drug Administration (FDA)

FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

Leadership, Goals, and Missions Drive ONS’s Work

Leadership, Goals, and Missions Drive ONS’s Work

FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

Nursing Considerations for Ovarian Cancer Survivorship Care

Nursing Considerations for Ovarian Cancer Survivorship Care

Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

Genetics & genomics

Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

Clinical practice

Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

Treatment side effects

Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

Food for Thought: Prevent and Screen for Malnutrition in Patients with Cancer

Clinical practice

Food for Thought: Prevent and Screen for Malnutrition in Patients With Cancer

Nurses Are the Key to Achieving Health Equity

Nurses Are the Key to Achieving Health Equity

FDA Approves Asparaginase Erwinia Chrysanthemi for Leukemia and Lymphoma

U.S. Food and Drug Administration (FDA)

FDA Approves Asparaginase Erwinia Chrysanthemi for Leukemia and Lymphoma

Strong Social Relationships Strengthen and Sustain You

Nurse well-being

Strong Social Relationships Strengthen and Sustain You

Immunotherapy Extends Survival in Uveal Melanoma

Immunotherapy Extends Survival in Uveal Melanoma

Oncology Drug Reference Sheet: Tepotinib

Drug Reference Sheet

Oncology Drug Reference Sheet: Tepotinib

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

U.S. Food and Drug Administration (FDA)

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Cancer research

Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Conflict Engagement Helps Providers Focus on Care

Clinical practice

Conflict Engagement Helps Providers Focus on Care

When Grief Goes Beyond Burnout, Organizations Must Intervene

Grief & bereavement

When Grief Goes Beyond Burnout, Organizations Must Intervene

APRNs Are Essential in Survivorship Programs

Survivorship care plans

APRNs Are Essential in Survivorship Programs

Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care

Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care

Research Findings Confirm Link Between Communication and Safety

Research Findings Confirm Link Between Communication and Safety

Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills

Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills

Congratulations to ONS Director-at-Large Valerie Burger, RN, MA, MS, OCN®, CPN, whom the ONS Board of Directors selected as treasurer, and ONS Director-at-Large Darcy Burbage, DNP, RN, AOCN®, CBCN®, whom it selected as secretary, during its April 13, 2021, meeting.

ONS board of directors

Board Appoints Officers, Doubles Chapter Visits, Updates Navigator Position, and More

Nursing Considerations for Prostate Cancer Survivorship Care

Clinical practice

Nursing Considerations for Prostate Cancer Survivorship Care

Multimethod Approach Supports Providers’ Mental Health During COVID-19

Multimethod Approach Supports Providers’ Mental Health During COVID-19

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq™), a kinase inhibitor for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. FDA also approved the FoundationOne® CDx as a companion diagnostic for infigratinib.

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma

Maximize Your Words’ Healing Power

Clinical practice

Maximize Your Words’ Healing Power

Back to Top ▲